Eat Maccas for dinner three nights in a row and I guarantee you won’t feel too flash. Replace your deep fried goodies from the golden arches with a quinoa salad and your body will thank you.
The effects may be due to the link between our health and gut microbiome which is determined by what you eat. It’s been a hot topic in medical research for the past few years with health and wellness influencers beginning to promote all sorts of gut healing concoctions.
Specialist microbiome company Microba Life Sciences (ASX: MAP) is more reliable than your favourite Instagrammer, with world-leading technology for measuring the human gut microbiome.
The Company’s approach is two pronged, developing multiple clinical therapeutic compounds and offering gut microbiome testing services to doctors, researchers and consumers. Their combination of B2B and B2C offerings allows the Company to foster key relationships with multiple customers and gain market share across numerous segments where personalised medicine, nutrition and healthcare is growing.
Microba’s most recent product offering is specifically for health professionals. The product, which remains unnamed, will allow healthcare providers to glean important information from the gut microbiome of patients including opportunities to intervene and improve the microbiome via intervention which could include diet, lifestyle change or supplementation. Microba’s product will deliver clinicians with a report that will help them make decisions for their patients with 55 new clinical interventions and suggestions. These sorts of microbiome tests feed into the rising trend of personalised medicine.
Additionally, this service can be incorporated into both preventative and acute care, opening multiple opportunities for revenue.
Chief Scientific Officer, Associate Professor Lutz Krause said: “The new healthcare product delivers the latest clinical information available from gut microbiome testing. This encompasses information drawn from over 1,000 peer-reviewed publications and supporting data from Microba’s large proprietary Databank.”
Prior to a full scale market launch, Microba is giving a handful of clinicians access to the beta program which has been developed since 2018 when the Company launched their first test. This new product is the most comprehensive and clinically useful test currently available on the market.
The test will give actionable insights into patient health and will introduce clinicians to Microba’s brand, with the opportunity for cross referrals to their clinical compounds once approved.
Head of Healthcare Operations at Microba, Hayley Parcell said: “We have been working closely with health professionals to advance the clinical use of microbiome testing. As a leader in the field, we have worked to deliver the best microbiome test to assist them in supporting their patients’ health. We believe this new product will be a foundational shift in the industry and ultimately set a new benchmark for clinical microbiome testing.”
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
- Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
- How this company is developing medtech to support Indigenous community health - August 22, 2022
- A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
Leave a Comment
You must be logged in to post a comment.